Jens Nielsen

Prof. Dr. Jens Nielsen

Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

58Years (1969-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 1986 in Science
Verified
Journal Article
Closed access
PDF file
KBKlaus Bendtzen
Klaus Bendtzen
TMThomas Mandrup-Poulsen
Thomas Mandrup-Poulsen
JNJørn Nerup
Jørn Nerup
Jens NielsenJens Nielsen
Jens Nielsen
CDCharles A. Dinarello
Charles A. Dinarello
MSMorten Svenson
Morten Svenson
Activated mononuclear cells appear to be important effector cells in autoimmune beta cell destruction leading to insulin-dependent (type 1) diabetes mellitus. Conditioned medium from activated mononuclear cells (from human blood) is cytotoxic to isolated rat and human islets of Langerhans. This cytotoxic activity was eliminated from crude cytokine preparations by adsorption with immobilized, purified antibody to interleukin-1 (IL-1). The islet-inhibitory activity and the IL-1 activity (determined by its comitogenic effect on thymocytes) were recovered by acid wash. Purified natural IL-1 and recombinant IL-1 derived from the predominant p I 7 form of human IL-1, consistently inhibited the insulin response. The p I 6 and p I 5 forms of natural IL-1 were ineffective. Natural and recombinant IL-1 exhibited similar dose responses in their islet-inhibitory effect and their thymocyte-stimulatory activity. Concentrations of IL-1 that inhibited islet activity were in the picomolar range. Hence, monocyte-derived p I 7 IL-1 may contribute to islet cell damage and therefore to the development of insulin-dependent diabetes mellitus.

1 July 1982 in Nature
Verified
Journal Article
Closed access
SBSteinunn Baekkeskov
Steinunn Baekkeskov
Jens NielsenJens Nielsen
Jens Nielsen
BMBirgitte Marner
Birgitte Marner
TBTorben Bilde
Torben Bilde
JLJohnny Ludvigsson
Johnny Ludvigsson
ALAke Lernmark
Ake Lernmark

1 January 1986 in Diabetologia
Verified
Journal Article
Closed access
PDF file
TMThomas Mandrup-Poulsen
Thomas Mandrup-Poulsen
KBK. Bendtzen
K. Bendtzen
JNJ. Nerup
J. Nerup
CDC. A. Dinarello
C. A. Dinarello
MSM. Svenson
M. Svenson
Jens NielsenJens Nielsen
Jens Nielsen

1 February 2001 in Diabetes
Verified
Journal Article
Closed access
PDF file
Jens NielsenJens Nielsen
Jens Nielsen
EGE D Galsgaard
E D Galsgaard
AMA Møldrup
A Møldrup
BFB N Friedrichsen
B N Friedrichsen
NBN Billestrup
N Billestrup
CCC Carlsson
C Carlsson
Substantial new information has accumulated on molecular mechanisms of pancreas development, regulation of beta-cell gene expression, and the role of growth factors in the differentiation, growth, and regeneration of beta-cells. The present review focuses on some recent studies on the mechanism of action of cytokines such as growth hormone (GH) and prolactin (PRL) in beta-cell proliferation and gene expression-in particular, the role of signal transducers and activators of transcription (STAT) proteins. The implication of the discovery of suppressors of cytokine signaling (SOCS) proteins for the interaction between stimulatory and inhibitory cytokines, including GH, PRL, leptin, and the proinflammatory cytokines interleukin-1 and interferon-gamma, in beta-cell survival is not yet clear. Recent studies indicate a role of cell adhesion molecules and the delta-like protein preadipocyte factor 1/fetal antigen 1 (Pref-1/FA-1) in cytokine-induced beta-cell growth and development. Surprisingly, glucagon-like peptide-1 (GLP-1) was recently found to stimulate not only insulin secretion but also beta-cell replication and differentiation, which may present a new perspective in treatment of type 2 diabetes. Together with the intriguing reports on positive effects of insulin on both beta-cell growth and function, a picture is emerging of an integrated network of signaling events acting in concert to control beta-cell mass adaptation to insulin demand.

1 August 1985 in Allergy
Verified
Journal Article
Closed access
PDF file
TMThomas Mandrup-Poulsen
Thomas Mandrup-Poulsen
KBK. Bendtzen
K. Bendtzen
Jens NielsenJens Nielsen
Jens Nielsen
GBG. Bendixen
G. Bendixen
JNJ. Nerup
J. Nerup

1 March 2006 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
BFBirgitte N Friedrichsen
Birgitte N Friedrichsen
NNNicole Neubauer
Nicole Neubauer
YLYing C Lee
Ying C Lee
VGVivian K Gram
Vivian K Gram
NBNiels Blume
Niels Blume
AMAnnette Møldrup
Annette Møldrup
The incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), have been suggested to act as β-cell growth factors and may therefore be of critical importance for the maintenance of a proper β-cell mass. We have investigated the molecular mechanism of incretin-induced β-cell replication in primary monolayer cultures of newborn rat islet cells. GLP-1, GIP and the long-acting GLP-1 derivative, lira-glutide, increased β-cell replication 50–80% at 10–100 nM upon a 24 h stimulus, whereas glucagon at a similar concentration had no significant effect. The stimulatory effect of GLP-1 and GIP was efficiently mimicked by the adenylate cyclase activator, forskolin, at 10 nM (~90% increase) and was additive (~170–250% increase) with the growth response to human growth hormone (hGH), indicating the use of distinct intracellular signalling pathways leading to mitosis by incretins and cytokines, respectively. The response to both GLP-1 and GIP was completely blocked by the protein kinase A (PKA) inhibitor, H89. In addition, the phosphoinositol 3-kinase (PI3K) inhibitor wortmannin and the mitogen-activated protein kinase kinase (MEK) inhibitor PD98059, both inhibited GLP-1- and GIP-stimulated proliferation. The p38 mitogen-activated protein kinase (MAPK) inhibitor, SB203580, had no inhibitory effect on either GLP-1 or GIP stimulated proliferation. Cyclin Ds act as molecular switches for the G0/G1-S phase transition in many cell types and we have previously demonstrated hGH-induced cyclin D2 expression in the insulinoma cell line, INS-1. GLP-1 time-dependently induced the cyclin D1 mRNA and protein levels in INS-1E, whereas the cyclin D2 levels were unaffected. However, minor effect of GLP-1 stimulation was observed on the cyclin D3 mRNA levels. Transient transfection of a cyclin D1 promoter-luciferase reporter construct into islet monolayer cells or INS-1 cells revealed approximately a 2–3 fold increase of transcriptional activity in response to GLP-1 and GIP, and a 4–7 fold increase in response to forskolin. However, treatment of either cell type with hGH had no effect on cyclin D1 promoter activity. The stimulation of the cyclin D1 promoter by GLP-1 was inhibited by H89, wortmannin, and PD98059. We conclude that incretin-induced β-cell replication is dependent on cAMP/PKA, p42 MAPK and PI3K activities, which may involve transcriptional induction of cyclin D1. GLP-1, GIP and liraglutide may have the potential to increase β-cell replication in humans which would have significant impact on long-term diabetes treatment.